PMID- 21699369
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20151119
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 27
IP  - 8
DP  - 2011 Aug
TI  - Begin with the real-world patients of non-goal-achieved hypercholesterolemia in 
      taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
PG  - 1645-51
LID - 10.1185/03007995.2011.594425 [doi]
AB  - OBJECTIVE: To assess the efficacy, safety, and tolerability of a combination of 
      10 mg ezetimibe and 20 mg simvastatin in Taiwanese patients with 
      hypercholesterolemia. RESEARCH DESIGN AND METHODS: A prospective, open-label, 
      multi-center, hospital-based cohort study was conducted to evaluate the efficacy, 
      safety, and tolerability of a single tablet combination of ezetimibe/simvastatin 
      for the treatment of hypercholesterolemia. Taiwanese adults without low-density 
      lipoprotein cholesterol (LDL-C) goal achievement, based on the National 
      Cholesterol Education Program Adult Treatment Panel III guidelines, were treated 
      with ezetimibe/simvastatin once daily for 6 weeks. The primary endpoint was the 
      percentage of patients achieving LDL-C treatment goals after 6 weeks of 
      treatment. Secondary endpoints included percentage change from baseline of LDL-C, 
      total cholesterol, high-density lipoprotein cholesterol, and triglyceride. Safety 
      and tolerability were assessed via clinical and laboratory examinations. The 
      clinicaltrial.gov identifier of this study was NCT00654628. RESULTS: In total, 
      173 patients with a mean age of 57.9 +/- 10.4 years were included. Of these, 57.8% 
      were female and the average body mass index was 25.5 +/- 3.4 kg/m(2). After 6 weeks 
      of treatment, the great majority of the patients had reached their treatment 
      goals (90.4% for LDL-C; 87% for TC; and 59% for TG). LDL-C levels were 
      significantly reduced from 156.8 +/- 30.8 mg/dL at baseline to 75.9 +/- 25.4 mg/dL 
      (51.4%, P < 0.0001) after only 6 weeks of therapy. Forty-nine adverse events 
      (AEs), including one non-drug related serious AE, were reported. For non-serious 
      AEs, the most common reported AEs during the entire study period were myalgia and 
      upper respiratory infection (both n = 7). Nine patients dropped out of the study, 
      reportedly due to AEs. CONCLUSIONS: A single tablet combination of 10 mg 
      ezetimibe and 20 mg simvastatin in Taiwanese patients with hypercholesterolemia 
      provided high LDL-C goal attainment rates and resulted in significant reductions 
      in LDL-C.
FAU - Huang, Jui-Chu
AU  - Huang JC
AD  - Division of Metabolism and Endocrinology, Department of Internal Medicine, Chang 
      Gung Memorial Hospital, Taoyuan, Taiwan.
FAU - Lee, Tao-Yu
AU  - Lee TY
FAU - Liou, Miaw-Jene
AU  - Liou MJ
FAU - Lin, Chi-Min
AU  - Lin CM
FAU - Pei, Dee
AU  - Pei D
FAU - Chen, Zhih-Cherng
AU  - Chen ZC
FAU - Liu, Rue-Tsuan
AU  - Liu RT
FAU - Kwok, Ching-Fai
AU  - Kwok CF
LA  - eng
SI  - ClinicalTrials.gov/NCT00654628
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110623
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Azetidines)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Drug Combinations)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Triglycerides)
RN  - AGG2FN16EV (Simvastatin)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anticholesteremic Agents/*administration & dosage/adverse effects
MH  - Azetidines/*administration & dosage/adverse effects
MH  - Cholesterol, HDL/*blood
MH  - Cholesterol, LDL/*blood
MH  - Drug Combinations
MH  - Ezetimibe
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse 
      effects
MH  - *Hypercholesterolemia/blood/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Simvastatin/*administration & dosage/adverse effects
MH  - Taiwan
MH  - Time Factors
MH  - Triglycerides/*blood
EDAT- 2011/06/28 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/06/25 06:00
PHST- 2011/06/25 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
AID - 10.1185/03007995.2011.594425 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2011 Aug;27(8):1645-51. doi: 10.1185/03007995.2011.594425. 
      Epub 2011 Jun 23.